BREAST 润色咨询

BREAST

出版年份:1992 年文章数:1786 投稿命中率: 开通期刊会员,数据随心看

出版周期:Quarterly 自引率:6.0% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向:乳腺癌<br>经验分享:3月15号投稿,with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号under review,九月八号两个审稿人审稿,目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0<br>偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号直接跳过了with editor直接进入under review,九月八号两个审稿人接受审稿,目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向:临床试验<br>经验分享:2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0<br>经验分享:刚才写错了,应该是with editor要整整28天,然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0<br>经验分享:一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0<br>经验分享:meta分析,八天到编辑手里,两天后被拒,说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=371, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久,该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521447, encodeId=4c6852144e5b, content=三个星期了,还在with editor .....好抓狂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b5f1701449, createdName=愽1b36c785, createdTime=Tue Apr 19 15:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2023-03-23 1228cbd9m21暂无昵称

    偏重的研究方向:乳腺癌
    经验分享:3月15号投稿,with editor一个星期了还没变化

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向:乳腺癌<br>经验分享:3月15号投稿,with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号under review,九月八号两个审稿人审稿,目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0<br>偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号直接跳过了with editor直接进入under review,九月八号两个审稿人接受审稿,目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向:临床试验<br>经验分享:2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0<br>经验分享:刚才写错了,应该是with editor要整整28天,然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0<br>经验分享:一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0<br>经验分享:meta分析,八天到编辑手里,两天后被拒,说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=371, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久,该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521447, encodeId=4c6852144e5b, content=三个星期了,还在with editor .....好抓狂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b5f1701449, createdName=愽1b36c785, createdTime=Tue Apr 19 15:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2022-09-12 ms3000000995770335

    偏重的研究方向:乳腺癌;人工智能;病理组学
    经验分享:九月二号投稿,九月五号under review,九月八号两个审稿人审稿,目前还没有变化

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向:乳腺癌<br>经验分享:3月15号投稿,with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号under review,九月八号两个审稿人审稿,目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0<br>偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号直接跳过了with editor直接进入under review,九月八号两个审稿人接受审稿,目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向:临床试验<br>经验分享:2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0<br>经验分享:刚才写错了,应该是with editor要整整28天,然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0<br>经验分享:一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0<br>经验分享:meta分析,八天到编辑手里,两天后被拒,说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=371, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久,该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521447, encodeId=4c6852144e5b, content=三个星期了,还在with editor .....好抓狂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b5f1701449, createdName=愽1b36c785, createdTime=Tue Apr 19 15:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2022-09-12 ms3000000995770335

    审稿速度:2.0
    偏重的研究方向:乳腺癌;人工智能;病理组学
    经验分享:九月二号投稿,九月五号直接跳过了with editor直接进入under review,九月八号两个审稿人接受审稿,目前任然这种状态

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向:乳腺癌<br>经验分享:3月15号投稿,with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号under review,九月八号两个审稿人审稿,目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0<br>偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号直接跳过了with editor直接进入under review,九月八号两个审稿人接受审稿,目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向:临床试验<br>经验分享:2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0<br>经验分享:刚才写错了,应该是with editor要整整28天,然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0<br>经验分享:一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0<br>经验分享:meta分析,八天到编辑手里,两天后被拒,说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=371, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久,该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521447, encodeId=4c6852144e5b, content=三个星期了,还在with editor .....好抓狂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b5f1701449, createdName=愽1b36c785, createdTime=Tue Apr 19 15:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2022-08-06 ms8000002072646838

    偏重的研究方向:临床试验
    经验分享:2022-8-5投稿

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向:乳腺癌<br>经验分享:3月15号投稿,with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号under review,九月八号两个审稿人审稿,目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0<br>偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号直接跳过了with editor直接进入under review,九月八号两个审稿人接受审稿,目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向:临床试验<br>经验分享:2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0<br>经验分享:刚才写错了,应该是with editor要整整28天,然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0<br>经验分享:一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0<br>经验分享:meta分析,八天到编辑手里,两天后被拒,说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=371, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久,该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521447, encodeId=4c6852144e5b, content=三个星期了,还在with editor .....好抓狂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b5f1701449, createdName=愽1b36c785, createdTime=Tue Apr 19 15:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2022-04-27 cindyspinach

    投稿命中率:50.0
    经验分享:刚才写错了,应该是with editor要整整28天,然后才决定是送审还是直接拒稿。一审时间用21天。

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向:乳腺癌<br>经验分享:3月15号投稿,with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号under review,九月八号两个审稿人审稿,目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0<br>偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号直接跳过了with editor直接进入under review,九月八号两个审稿人接受审稿,目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向:临床试验<br>经验分享:2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0<br>经验分享:刚才写错了,应该是with editor要整整28天,然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0<br>经验分享:一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0<br>经验分享:meta分析,八天到编辑手里,两天后被拒,说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=371, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久,该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521447, encodeId=4c6852144e5b, content=三个星期了,还在with editor .....好抓狂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b5f1701449, createdName=愽1b36c785, createdTime=Tue Apr 19 15:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2022-04-27 cindyspinach

    投稿命中率:50.0
    经验分享:一审时间28天

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向:乳腺癌<br>经验分享:3月15号投稿,with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号under review,九月八号两个审稿人审稿,目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0<br>偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号直接跳过了with editor直接进入under review,九月八号两个审稿人接受审稿,目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向:临床试验<br>经验分享:2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0<br>经验分享:刚才写错了,应该是with editor要整整28天,然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0<br>经验分享:一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0<br>经验分享:meta分析,八天到编辑手里,两天后被拒,说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=371, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久,该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521447, encodeId=4c6852144e5b, content=三个星期了,还在with editor .....好抓狂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b5f1701449, createdName=愽1b36c785, createdTime=Tue Apr 19 15:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2021-03-12 1465389cm38暂无昵称

    Mar 11投稿 Mar 12 with editor

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向:乳腺癌<br>经验分享:3月15号投稿,with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号under review,九月八号两个审稿人审稿,目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0<br>偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号直接跳过了with editor直接进入under review,九月八号两个审稿人接受审稿,目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向:临床试验<br>经验分享:2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0<br>经验分享:刚才写错了,应该是with editor要整整28天,然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0<br>经验分享:一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0<br>经验分享:meta分析,八天到编辑手里,两天后被拒,说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=371, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久,该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521447, encodeId=4c6852144e5b, content=三个星期了,还在with editor .....好抓狂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b5f1701449, createdName=愽1b36c785, createdTime=Tue Apr 19 15:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2016-03-03 旭哥

    投稿命中率:25.0
    经验分享:meta分析,八天到编辑手里,两天后被拒,说不适合他们的读者群体。

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向:乳腺癌<br>经验分享:3月15号投稿,with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号under review,九月八号两个审稿人审稿,目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0<br>偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号直接跳过了with editor直接进入under review,九月八号两个审稿人接受审稿,目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向:临床试验<br>经验分享:2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0<br>经验分享:刚才写错了,应该是with editor要整整28天,然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0<br>经验分享:一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0<br>经验分享:meta分析,八天到编辑手里,两天后被拒,说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=371, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久,该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521447, encodeId=4c6852144e5b, content=三个星期了,还在with editor .....好抓狂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b5f1701449, createdName=愽1b36c785, createdTime=Tue Apr 19 15:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2020-07-01 147c079dm30(暂无昵称)

    请问该期刊With Editor一般多久,该状态主要干什么

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向:乳腺癌<br>经验分享:3月15号投稿,with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号under review,九月八号两个审稿人审稿,目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0<br>偏重的研究方向:乳腺癌;人工智能;病理组学<br>经验分享:九月二号投稿,九月五号直接跳过了with editor直接进入under review,九月八号两个审稿人接受审稿,目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向:临床试验<br>经验分享:2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0<br>经验分享:刚才写错了,应该是with editor要整整28天,然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0<br>经验分享:一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0<br>经验分享:meta分析,八天到编辑手里,两天后被拒,说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=371, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久,该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521447, encodeId=4c6852144e5b, content=三个星期了,还在with editor .....好抓狂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b5f1701449, createdName=愽1b36c785, createdTime=Tue Apr 19 15:31:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2016-04-19 愽1b36c785

    三个星期了,还在with editor .....好抓狂

    1

    展开1条回复
共34条页码: 1/4页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分